Tag Archives: VC

China Firm wtih Cross-Border VC Arm Raises New $1B RMB Early Stage Fund

19 Jul

A strategic consulting firm with offices in USA and China has a venture capital arm that invests in life sciences. Alongside investments, the firm advises life science companies on strategic partnerships (manufacturers, distributors) in the Asian market by providing resources in the network. In addition to a $10M fund closed at the end of 2016, the firm has a new ¥1 billion RMB (approx. $150M US dollar equivalent) fund which invests majorly in China local healthcare companies or helps the companies outside of China grow well in Asia market. The firm is seeking five new investments within the next year, and typically makes $1M – $5M dollar investments per company in Series B and C rounds. The firm focuses on the startups in U.S., China, Canada, and Europe based companies, though is open to companies on a global-level.

The firm is indication agnostic and open to technology in all sectors of life science (medical devices, therapeutics, diagnostics, and digital health) while having the most experience in biotech/medtech. In terms of phase of development, the firm requires the company to at least have a prototype, and for therapeutics to be in clinical trials, preferably after Phase 2. The firm will also look at on-the-market products of medical device, lab equipment and drug development enabling technology.

The firm requires the company to be in Series A, B, or C. The firm prefers the company to have or seek to have their technology or products in Asia market.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: VC Firm Seeks to Invest in Medical Device, Scientific Instrument, and Digital Health Technologies in the Midwest and Southern California

12 Jul

A venture capital firm located in the midwest USA with several offices nationwide. The firm has 3 funds, the third of which they are investing from. The third fund has a vintage year of 2016. The firm currently is looking to make investments from this fund typically in the $.25-1M range with 2x that amount saved for follow on investments. The firm is looking to make 10 investments a year through 2019. The firm typically invests in companies raising Seed Investments, Seed Extensions, or Series A investments. The firm tends to lead 30-40% of their investments and co-invests in the rest. The firm looks at companies primarily in the Midwest, but is also interested in companies in Southern California.

The firm looks for investments primarily in the healthcare IT, medical devices, scientific instruments, and agriculture technology spaces. For the healthcare IT, agriculture technology, and scientific instrument companies, the firm prefers for the companies to have demonstrated product-market fit, some decent revenue traction, and a good revenue trend-line. For the medical device companies, the firm prefers to invest in companies that are just prior to FDA approval or are going through the FDA approval process. The firm’s focus on IT is much broader than just healthcare IT and is willing to consider IT companies beyond the healthcare sector.

The firm looks for companies with experienced management teams. When leading the investments, the firm requests a board seat and when co-investing, the company requests board observer rights if possible.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 1: Korean VC Firm with Pharma Affiliation Seeks to Invest in Early Stage Therapeutics Assets, Most Interested in Oncology and Autoimmune Disease

5 Jul

A Seoul-based venture capital firm founded in 2015 and affiliated with a leading pharmaceutical company in South Korea closed their first fund in 2016 and has recently raised a second fund of approximately $60M USD. The firm has made 8 investments to date, in 3 Korean and 5 USA-based companies. The firm continues to seek global opportunities. The firm generally participates in financings of Series B and beyond, participating in Series A rounds on a case-by-case basis. However, the firm has started to look for earlier stage opportunities and is most interested in spin-out assets and forming new companies in South Korea. Within this angle, the firm is highly interested in companies who are interested in entering the Korean market and looking to leverage on the capital and clinical infrastructure in South Korea.

The firm is focused on therapeutics companies and does not invest in medical devices, diagnostics, or digital health. The firm is open to considering assets of very early stages, even those as early as lead optimization phase. The firm considers various modalities, including antibodies, small molecules, and cell therapy. Currently, the firm is not interested in gene therapy. Indication-wise, the firm is most interested in oncology and autoimmune diseases but has recently looked at fibrotic diseases and certain rare diseases as well.

With regards to companies raising a Series A round, the firm prefers working with experienced management teams with high-profile scientific founders being involved. The firm incorporates a different strategy depending on the company’s headquarters. For companies based in South Korea, the firm serves as a hands-on, active investor and seeks board representation. In the USA, the firm prefers to be a more passive investor and generally seeks to co-invest with established venture capital firms that have a footprint in the USA.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 2: Hong Kong Boutique VC Firm Invests in All Kinds of Healthcare Technologies and Most Interested in Large Disease Markets of Unmet Medical Need

5 Jul

A boutique venture capital firm founded in Hong Kong currently manages a $100M USD fund and a $200M RMB fund. The fund is industry agnostic within China while it focuses only on healthcare ex-China. The firm generally participates in Series A or B rounds but would also consider seed and growth-stage funding. Typical equity investment size ranges from $1-5M. The firm is open to both leading and co-investing. The firm is actively seeking new opportunities from across the world with a focus on companies in China, U.S., Europe, and Israel. The firm helps portfolio companies get into massive and fast-growing markets of China and Asia, and assists Chinese companies to expand abroad.

The firm is opportunistic across all subsectors of healthcare. Within MedTech, the firm is most interested in medical devices, artificial intelligence, robotics, and mobile health. The firm is seeking post-prototype innovations that are FDA cleared or are close to receiving clearance. Within therapeutics, the firm is interested in therapeutics for large disease markets such as oncology, neurology, and metabolic diseases. The firm is open to all modalities with a special interest in immunotherapy and cell therapy.

The firm is in search of ambitious companies with strong, experienced management teams. The firm takes a hands-on approach to portfolio companies and can work with incomplete teams. The firm can contribute expertise in essential services: branding, marketing, channel development, overseas expansion, human resources and finance. The firm may also request distribution or negotiation rights in China.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 1: Global VC Firm Headquartered in Asia Invests in All Parts of Therapeutics, Medical Devices, Diagnostics, and Digital Health

28 Jun

A venture capital firm founded in 2005 has multiple offices throughout Asia, New York, and San Diego. The firm has closed its fifth fund in 2017 and is currently raising a sixth fund, which the firm is targeting to be the largest fund to date. The firm continues to actively seek investment opportunities across a wide range of industries. 1/3 of the fund is dedicated to global/USA-based life sciences and healthcare investments, while the rest of the fund will focus on investing in Asia-based companies. On average, the initial size of investment is in the $2-5M range but the firm has the capacity to invest more in companies they identify as a strong fit. The firm can participate anywhere from Seed to Series B, but Series A is their sweet spot.

The firm is an opportunistic investor and will consider therapeutics, medical devices, diagnostics, and healthcare IT companies. However, the firm will generally avoid single therapeutic assets and those that are pre-clinical or earlier. The firm is open to novel medical devices of all FDA regulatory pathways, including 510k and PMA. The firm is strongly interested in platform plays, or technologies that have implications in multiple disease areas or indications. Examples include novel drug delivery platforms, drug discovery platforms that leverage AI or machine learning, regenerative medicine, etc.

The firm considers the management team’s character and entrepreneurial spirit – more so than the team’s experience – as one of the most important factors in the investment screening process. Each partner of the firm will dedicate their time to become acquainted with the management team and determine their degree of fit. The targeted market and the company’s competitive edge are also important considerations. The firm prefers to act as the lead investor and will seek board representation, but is also open to co-investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 2: USA-Based Venture Capital Firm Invests in Medical Devices, Diagnostics, and Digital Health with Strong Interests in Applications of AI and Machine Learning

28 Jun

A venture capital company founded in 2005 and located in California manages just under $70 million in assets across 2 funds and makes equity investments into companies ranging from a few hundred thousand dollars to $2 million with additional capital reserved for follow on rounds. The firm is looking for companies located throughout the United States and plans to make 4 new investments over the next 6-9 months.

The firm is looking for companies developing Medical Devices and Diagnostics, Healthcare IT products and Life Science Research Tools with an emphasis on fast to market low capital intense products that reduce the cost of delivering quality healthcare. For Healthcare IT investments the firm is most interested in machine learning and artificial intelligence (AI) applications and is generally not interested in Telehealth and EMR solutions. The firm is open to all sub-sectors and indications in the Medical technology space except for those targeting diseases and disorders of the spine. The firm will invest in both seed and later stage companies.

The firm is looking for companies with skilled and experienced management teams. The firm generally looks to take a board seat into companies after investment and play and active role in the management. The firm is willing to invest in both public and privately held companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 3: VC Firm Seeks Investment Opportunities in Digital Health and Medical Device Technologies that Address Problems of Large Unmet Need in Healthcare

28 Jun

A venture capital firm spun out of a leading university looks to provide primarily seed stage financings to companies ranging from $100K – $500k initially with up to $5-6 million provided over the lifetime of the investment. The firm prefers to invest in companies in the Eastern United States but is open to considering companies from around the globe. The firm could make as many as 6-7 investments over the next 6-9 months.

The firm is looking for companies working in sectors of digital health and more selectively medical devices. The firm is only interested in companies that are targeting very larger markets/unmet needs and is not interested in companies that require FDA Approval. The firm is especially interested in companies utilizing software for the optimization of various products and processes within healthcare. The firm is not interested in consumer-facing products.

The firm is very open to working with young entrepreneurs and generally looks to take a board seat following the investment. The firm is looking for companies with the potential to become very large organizations capable of being worth hundreds of millions of dollars.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

%d bloggers like this: